Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
The Medicines Company v. Mylan Inc. et al
Case Number:
1:11-cv-01285
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
October 30, 2017
Mylan Scores Costs After Win In Blood-Thinner IP Row
Mylan on Monday scored nearly all of the litigation costs it requested in a six-year dispute with The Medicines Co. over a generic version for the blood-thinner Angiomax, with an Illinois federal judge awarding $217,632 after the Federal Circuit found Mylan's generic did not infringe TMC's patents.
-
October 28, 2014
Medicines Co. Beats Mylan In Generic-Angiomax Fight
An Illinois federal court ruled Monday that Mylan Inc.'s proposed generic version of the anticoagulant Angiomax infringed one of The Medicines Co.'s patents for the drug and held that Mylan had failed to prove the patent was unenforceable or invalid.
-
May 16, 2014
Mylan Curbs Medicines Co.'s Expert In Angiomax Patent Trial
An Illinois federal judge on Thursday partially granted a motion from Mylan Inc. to limit The Medicines Co.'s expert testimony in an upcoming patent trial over Mylan's planned generic version of anticoagulant drug Angiomax.
-
February 24, 2011
Medicines Co. Sues Mylan Over Generic Angiomax
The Medicines Co. filed a patent infringement suit against Mylan Inc. in an Illinois federal court Wednesday in an effort to block the defendant's planned generic version of its anti-coagulant drug Angiomax.